These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23260348)

  • 1. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
    Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
    Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDE2 and PDE10, but not PDE5, inhibition affect basic auditory information processing in rats.
    Reneerkens OA; Sambeth A; Blokland A; Prickaerts J
    Behav Brain Res; 2013 Aug; 250():251-6. PubMed ID: 23688598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
    Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.
    Morriello GJ; Dwyer MP; Chen Y; Ginetti AT; Xu S; Lu J; Abeywickrema P; Wang D; Crespo A; Cabalu TD; Wilson JE; Stachel SJ; Paone DV; Sinz C
    Bioorg Med Chem Lett; 2021 Jul; 44():128082. PubMed ID: 33991626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
    Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.
    Qiu X; Huang Y; Wu D; Mao F; Zhu J; Yan W; Luo HB; Li J
    Bioorg Med Chem; 2018 Jan; 26(1):119-133. PubMed ID: 29174506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.
    Aspiotis R; Deschênes D; Dubé D; Girard Y; Huang Z; Laliberté F; Liu S; Papp R; Nicholson DW; Young RN
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5502-5. PubMed ID: 20709547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
    Dan A; Shiyama T; Yamazaki K; Kusunose N; Fujita K; Sato H; Matsui K; Kitano M
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4085-90. PubMed ID: 16005625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery.
    Zagorska A; Partyka A; Bucki A; Gawalskax A; Czopek A; Pawlowski M
    Curr Med Chem; 2018; 25(29):3455-3481. PubMed ID: 29521210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.
    Redrobe JP; Rasmussen LK; Christoffersen CT; Bundgaard C; Jørgensen M
    Eur J Pharmacol; 2015 Aug; 761():79-85. PubMed ID: 25941078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new chemical tool for exploring the physiological function of the PDE2 isozyme.
    Chambers RJ; Abrams K; Garceau NY; Kamath AV; Manley CM; Lilley SC; Otte DA; Scott DO; Sheils AL; Tess DA; Vellekoop AS; Zhang Y; Lam KT
    Bioorg Med Chem Lett; 2006 Jan; 16(2):307-10. PubMed ID: 16275071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDE2 inhibition: potential for the treatment of cognitive disorders.
    Gomez L; Breitenbucher JG
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6522-7. PubMed ID: 24189054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.
    Huang XF; Cao YJ; Zhen J; Zhang DW; Kong R; Jiang WT; Xu Y; Song GQ; Ke HM; Liu L
    Bioorg Med Chem Lett; 2019 Feb; 29(3):481-486. PubMed ID: 30554955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species.
    Stachel SJ; Egbertson MS; Wai J; Machacek M; Toolan DM; Swestock J; Eddins DM; Puri V; McGaughey G; Su HP; Perlow D; Wang D; Ma L; Parthasarathy G; Reid JC; Abeywickrema PD; Smith SM; Uslaner JM
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1122-1126. PubMed ID: 29534798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel PDE10 inhibitors by a robust homogeneous screening assay.
    Li QY; Xu MK; Liu G; Christoffersen CT; Wang MW
    Acta Pharmacol Sin; 2013 Aug; 34(8):1116-20. PubMed ID: 23603978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.
    Wagner S; Scheunemann M; Dipper K; Egerland U; Hoefgen N; Steinbach J; Brust P
    Eur J Med Chem; 2016 Jan; 107():97-108. PubMed ID: 26562545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
    Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
    Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801.
    Reneerkens OAH; Rutten K; Bollen E; Hage T; Blokland A; Steinbusch HWM; Prickaerts J
    Behav Brain Res; 2013 Jan; 236(1):16-22. PubMed ID: 22951181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.